ASN 2025再添新证据,云顶新耀耐赋康进一步巩固IgA肾病一线治疗地位

e公司
Nov 13, 2025

近日,2025年第58届美国肾脏病协会肾脏周(ASN Kidney Week 2025)上,云顶新耀(01952.HK)核心产品耐赋康®(布地奈德肠溶胶囊)展示的多项中国真实世界研究(RWS)结果,受到行业关注。这些数据不仅验证了该药物在IgA肾病“对因治疗、尽早治疗、长期治疗”新管理策略中的核心价值,也证实了其对特殊人群的疗效,进一步巩固了其一线治疗地位。叠加中外指南背书与医保政策红利,这款全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10